vTv Therapeutics Inc.(VTVT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

vTv Therapeutics Inc. (VTVT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. VTVT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $12.4m in revenue and is scored on the micro-cap board instead. Top institutional holders of VTVT by reported 13-F value include Samsara BioCapital, MILLENNIUM MANAGEMENT, FMR, based on the most recent SEC filings. VTVT trades on the Nasdaq exchange and files with the SEC under CIK 1641489. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for vTv Therapeutics Inc. directly from SEC EDGAR.

Revenue

$0.00

Net Income

$-13.1M

VTVT key financials by period

vTv Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202410-K$1.0M$-18.5M—
FY 202210-K$2.0M$-19.2M—
FY 202110-K$4.0M$-13.0M—
FY 202010-K$6.4M$-8.5M-184.8%
FY 201910-K$2.8M$-13.0M—
FY 201810-K$12.4M$-7.9M-159.4%

Institutions holding VTVT

Institutional investors reporting a position in vTv Therapeutics Inc. on SEC Form 13F.
InstitutionSharesValueReported
Samsara BioCapital298,496$11.2M2026-06-30
MILLENNIUM MANAGEMENT269,874$10.2M2026-06-30
FMR260,391$9.8M2026-06-30
Siren, L.L.C.163,000$6.1M2026-06-30
BAKER BROS. ADVISORS148,314$5.6M2026-06-30
VANGUARD CAPITAL MANAGEMENT94,463$3.6M2026-06-30
Trails Edge Capital Partners85,192$3.2M2026-06-30
Aisling Capital Management50,000$1.9M2026-06-30
MARSHALL WACE, LLP39,560$1.5M2026-06-30
GEODE CAPITAL MANAGEMENT32,470$1.2M2026-06-30
SEC EDGAR: CIK 1641489 →
VTVT

vTv Therapeutics Inc.

VTVT
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $12.4M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$0

Net Income

Q2 2026
EDGAR

$-13.05M

ROIC

Q2 2026
EDGAR

-70.9%

Top Institutional Holders

as of Q2 2026
$60.51M total
Samsara BioCapital, LLC
$11.24M0.0%
MILLENNIUM MANAGEMENT LLC
$10.16M+30.8%
FMR LLC
$9.80M0.0%
Siren, L.L.C.
$6.14M0.0%
BAKER BROS. ADVISORS LP
$5.58M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$3.56M-13.3%
Trails Edge Capital Partners, LP
$3.21M-39.0%
Aisling Capital Management LP
$1.88MNew
MARSHALL WACE, LLP
$1.49M+195.5%
GEODE CAPITAL MANAGEMENT, LLC
$1.22M-1.3%

Financial Trends

Revenue & Net Income

Loading ratio trend…